E. Ohman J or Asset Management AB Has $7.67 Million Stock Position in DexCom, Inc. $DXCM

Key Points

• E. Ohman J or Asset Management AB increased its stake in DexCom by 49% to 115,492 shares, worth about $7.67 million at the end of the quarter.
• DexCom beat quarterly EPS estimates ($0.68 vs. $0.65) and reported $1.26 billion in revenue (up 13.1% year-over-year), while analysts have a consensus "Moderate Buy" with an average price target of $85.50.
• EVP Michael Jon Brown sold 1,700 shares, reducing insider ownership to 0.32%, while institutional investors hold roughly 97.75% of the stock.

E. Ohman J or Asset Management AB increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 49.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 115,492 shares of the medical device company's stock after acquiring an additional 38,000 shares during the quarter. E. Ohman J or Asset Management AB's holdings in DexCom were worth $7,665,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of DXCM. Vanguard Group Inc. grew its position in DexCom by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company's stock worth $3,327,897,000 after purchasing an additional 1,133,638 shares during the last quarter. Norges Bank acquired a new position in shares of DexCom during the second quarter valued at about $453,279,000. Groupama Asset Managment raised its position in shares of DexCom by 79,043.1% during the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company's stock valued at $350,601,000 after buying an additional 4,011,438 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of DexCom by 260.7% in the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company's stock valued at $333,630,000 after buying an additional 2,762,504 shares during the period. Finally, Federated Hermes Inc. lifted its stake in shares of DexCom by 82.1% in the second quarter. Federated Hermes Inc. now owns 3,633,139 shares of the medical device company's stock valued at $317,137,000 after buying an additional 1,638,407 shares during the period. 97.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00. Following the completion of the transaction, the executive vice president directly owned 112,904 shares in the company, valued at $7,321,824.40. This represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.32% of the stock is owned by company insiders.

DexCom Stock Down 1.5%

Shares of DXCM opened at $65.94 on Tuesday. The stock has a market cap of $25.38 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 1.30 and a beta of 1.48. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a 50-day moving average price of $70.40 and a two-hundred day moving average price of $67.93.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period in the prior year, the company posted $0.45 EPS. The company's revenue was up 13.1% compared to the same quarter last year. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DXCM shares. Citigroup boosted their price target on DexCom from $77.00 to $84.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. Canaccord Genuity Group set a $95.00 price objective on DexCom and gave the stock a "buy" rating in a research report on Friday, February 13th. BTIG Research restated a "buy" rating and set a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Wells Fargo & Company cut their target price on DexCom from $93.00 to $85.00 and set an "overweight" rating for the company in a research note on Friday, February 13th. Finally, Leerink Partners reaffirmed an "outperform" rating and issued a $92.00 target price on shares of DexCom in a research report on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $85.50.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.